In this regard, Jokerst et al. [52] used samples from benign prostatic hypertrophy patients as controls, raising the possibility that levels of MINDIN could increase during prostatic hypertrophy above values seen in either normal or prostate cancer. The gene discussed is SPON2; the disease is Familial prostate cancer.